| HOME >> MEDICINE >> TECHNOLOGY |
LONDON, RESEARCH TRIANGLE PARK, N.C. and MISSISSAUGA, Ontario, April 18, 2011 /PRNewswire/ -- GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) submitted the response on 15 April 2011 to the U.S. Food and Drug Administration (FDA) Complete Response letter received on 30 November 2010 for the New Drug Application (NDA) for ezogabine*.
Ezogabine is an investigational anti-epileptic drug being studied for the adjunctive treatment of adults with partial-onset seizures.
For announcements regarding the regulatory status, including filing and approval information, of ezogabine outside the US (where it is called retigabine*), please visit www.gsk.com and www.valeant.com.
GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
About Valeant – Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant can be found at www.valeant.com.GlaxoSmithKline Enquiries:UK Media enquiries:
David Mawdsley
(020) 8047 5502Claire Brough
(020) 8047 5502Stephen Rea
(020) 8047 5502Alexandra Harrison
(020) 8047 5502Janet Morgan
(020) 8047 5502David Daley
(020) 8047 5502US Media enquiries:
Nancy Pekarek
(919) 483 2839Mary Anne Rhyne
(919) 483 2839Kevin Colgan
(919) 483 2839Sarah Alspach
(919) 483 2839European Analyst/Investor en
'/>"/>
| SOURCE Valeant Pharmaceuticals International, Inc. Copyright©2010 PR Newswire. All rights reserved |